Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Mallinckrodt
Medtronic
Baxter
Johnson and Johnson

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

ARIXTRA Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Arixtra, and what generic alternatives are available?

Arixtra is a drug marketed by Mylan Ireland Ltd and is included in one NDA.

The generic ingredient in ARIXTRA is fondaparinux sodium. There are fourteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the fondaparinux sodium profile page.

Drug patent expirations by year for ARIXTRA
Drug Prices for ARIXTRA

See drug prices for ARIXTRA

Recent Clinical Trials for ARIXTRA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Alliance Foundation Trials, LLC.N/A
Patient-Centered Outcomes Research InstituteN/A
G. d'Annunzio UniversityPhase 4

See all ARIXTRA clinical trials

Pharmacology for ARIXTRA
Drug ClassFactor Xa Inhibitor
Mechanism of ActionFactor Xa Inhibitors
Synonyms for ARIXTRA
104993-28-4
114870-03-0
119329-39-4
129051-67-8
147827-38-1
214767-51-8
350014-67-4
389064-08-8
393796-46-8
393796-99-1
412015-07-7
816468-88-9
AC1LCS4W
AC1NR037
AK607894
AKOS005146286
Arixtra (TN)
C31H43N3O49S8.10Na
C31H53N3O49S8
CHEBI:31632
CHEBI:61033
CHEMBL1200644
CHEMBL1201202
D01844
DB00569
decasodium salt
DTXSID10146903
Epitope ID:150913
Fondaparin sodium
Fondaparinux
Fondaparinux sodium
Fondaparinux sodium (JAN/USAN/INN)
Fondaparinux sodium [USAN:INN:BAN]
GSK-576428
GTPL6819
HSDB 7845
I06-1946
IC 85158
J177FOW5JL
MolPort-006-167-583
Natural heparin pentasaccharide
NTO
Org-31540
Quixidar
SC-28606
SCHEMBL17655218
SR 90107
SR 90107A
SR-90107
SR-90107A
TRISULFOAMINO HEPARIN PENTASACCHARIDE
UNII-J177FOW5JL
UNII-X0Q6N9USOZ
X0Q6N9USOZ
Xantidar
XEKSTYNIJLDDAZ-JASSWCPGSA-F
Y1945

US Patents and Regulatory Information for ARIXTRA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Ireland Ltd ARIXTRA fondaparinux sodium INJECTABLE;SUBCUTANEOUS 021345-001 Dec 7, 2001 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Mylan Ireland Ltd ARIXTRA fondaparinux sodium INJECTABLE;SUBCUTANEOUS 021345-004 May 28, 2004 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Mylan Ireland Ltd ARIXTRA fondaparinux sodium INJECTABLE;SUBCUTANEOUS 021345-002 May 28, 2004 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Mallinckrodt
Johnson and Johnson
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.